Summary of COVID-19 conestat alfa studies

1. Bernstein et al., Recombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the US

38 patient conestat alfa late treatment RCT: 78% lower mortality (p=0.29), 87% lower ventilation (p=0.08), 46% lower progression (p=0.07), and 52% shorter hospitalization (p=0.06).
RCT 38 hospitalized COVID-19 patients showing non-significant improvements with conestat alfa. Results of this manufacturer RCT are notably better than the non-manufacturer RCT [Urwyler].
Nov 2021, NCT04530136, https://clinicaltrials.gov/study/NCT04530136, https://c19p.org/bernstein

2. Urwyler et al., Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial

83 patient conestat alfa late treatment RCT: 238% higher mortality (p=0.26), 286% higher ventilation (p=0.26), 141% higher ICU admission (p=0.32), and 117% lower hospital discharge (p=0.12).
RCT 84 hospitalized COVID-19 patients showing higher mortality with conestat alfa (recombinant C1 inhibitor), without reaching statistical significance.
Oct 2023, Frontiers in Immunology, https://www.frontiersin.org/articles/10.3389/fimmu.2023.1255292/full, https://c19p.org/urwyler